The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy

Guo, Mei; You, Chengzhong; Wang, Dong; Luo, Biao; Wu, Yu-Heng; Chen, Yanuo; Li, Jianping; Pan, Meng; Zhao, Fengshu; Dou, Jun

doi:10.1016/j.biopha.2020.110804

Cited by 12 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like normal stem cells, CCSCs have a high capacity for differentiation and renewal, contributing to the maintenance of cancer, in addition to their latency capacity, which can hide and provide resistance to treatment. Therefore, these cells constitute an important target for immunotherapy [21].…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, strategies using cells and molecules that activate the immune system are being used, for instance, dendritic cells that present CCSCs to T cells. Anyhow, it is still necessary a better knowledge in regard to the CCSC signaling pathway and its escape mechanisms before the development of CCSC vaccines [21]. It is important to take into account that other tumor antigens such as DNA molecules, peptides and proteins may be used as targets for the vaccines.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines Against Different Types of Cancer: Literature Review

Dias¹,

Melo²

2021

J Pharma Res Rep

View full text Add to dashboard Cite

According to the World Health Organization, in 2018, cancer was considered the second leading cause of death in the world, corresponding to 9.6 million deaths. Faced with this situation, some alternatives to combat tumors in some organs were developed, such as immunotherapy involving vaccines. Among the vaccines already developed, Sipuleucel-T (Provenge®) can be mentioned, that has been approved by the Food and Drug Administration in 2010 for cases of metastatic prostate cancer; prophylactic bivalent and quadrivalent vaccines to human papillomavirus; the nanoparticulate liposomal RNA vaccine, the melanoma FixVac (BNT111); peptide-based vaccines, such as carcinoembryonic antigen, and those that involve antigen-loaded dendritic cells for the treatment of colorectal cancer, as well as colorectal cancer stem cell-based vaccines and, for cases of ovarian cancer, dendritic cell vaccines. In relation to breast cancer, research is aimed at both immunotherapy with dendritic cells pulsed with tumor antigens and vaccines that have a combined therapy of dendritic cells and Natural Killer cells. In general, vaccines promote the induction of helper and cytotoxic cells to thereby eliminate tumor cells. This characteristic of using dendritic cells with tumor antigens already processed and presented on the cell surface allows the questioning about the use of the term “vaccine”, since it does not correspond to conventional vaccines. Thus, the studies carried out in this area of immunotherapy, although complex and expensive, show promise in the treatment of several types of cancer, with great possibilities of positively impacting the lives of all those who suffer from the disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Vaccines Against Different Types of Cancer: Literature Review

Dias¹,

Melo²

2021

J Pharma Res Rep

View full text Add to dashboard Cite

show abstract

“…In these studies, mice immunization with CCSC lysates, followed by challenge with CT26 cells, significantly reduced tumor growth, and this was accompanied by a robust activation of an antitumor immune response. Furthermore, MUC1 overexpression in CD133+ CSCs significantly increased this effect, whereas MUC1 downregulation abrogated the effectiveness of this vaccine [229,230]. Similarly, following this approach, a MUC1-based autologous dendritic cell (DC) vaccine given to prostate cancer patients was reported to be safe in phase I/II studies and elicited a significant CD4+/CD8+ T cell response [231].…”

Section: Figurementioning

confidence: 99%

Cancer Stem Cells—Key Players in Tumor Relapse

Marzagalli

Fontana

Raimondi

et al. 2021

Cancers

102

View full text Add to dashboard Cite

Tumor relapse and treatment failure are unfortunately common events for cancer patients, thus often rendering cancer an uncurable disease. Cancer stem cells (CSCs) are a subset of cancer cells endowed with tumor-initiating and self-renewal capacity, as well as with high adaptive abilities. Altogether, these features contribute to CSC survival after one or multiple therapeutic approaches, thus leading to treatment failure and tumor progression/relapse. Thus, elucidating the molecular mechanisms associated with stemness-driven resistance is crucial for the development of more effective drugs and durable responses. This review will highlight the mechanisms exploited by CSCs to overcome different therapeutic strategies, from chemo- and radiotherapies to targeted therapies and immunotherapies, shedding light on their plasticity as an insidious trait responsible for their adaptation/escape. Finally, novel CSC-specific approaches will be described, providing evidence of their preclinical and clinical applications.

show abstract

“…Colorectal cancer is one of the most common malignancies in China, and is prone to occur in the sigmoid colon and rectum. In recent years, a number of reports have confirmed that MUC1 may be a dominant antigen for the diagnosis and targeted therapy for colorectal cancer ( 66 , 67 ).…”

Section: Muc1 Expression In Different Tumours and Its Clinical Signif...mentioning

confidence: 99%

Expression of MUC1 in different tumours and its clinical significance (Review)

Lan

Tai

2022

Mol Clin Oncol

View full text Add to dashboard Cite

Mucin 1 (MUC1) was the first discovered transmembrane protein of the mucin family; it normally covers epithelial cells of the mucous membrane, providing lubrication and protection. However, aberrant expression of MUC1 is involved in cancer development, invasion and metastasis. It has been reported that MUC1 upregulation is highly associated with the progression of different epithelial cancer types, such as lung, liver, pancreatic and breast cancer. Therefore, MUC1 can be used as a specific marker and a target for immunotherapy in clinical applications, and the detection of MUC1 expression levels can be used to diagnose the occurrence, metastasis, prognosis and recurrence of cancer. The present review summarizes the abnormal expression of MUC1 in different tumours and discusses its clinical significance, thereby highlighting the potential diagnostic and therapeutic significance of MUC1 in cancer.

show abstract

The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy

Cited by 12 publications

References 50 publications

Vaccines Against Different Types of Cancer: Literature Review

Vaccines Against Different Types of Cancer: Literature Review

Cancer Stem Cells—Key Players in Tumor Relapse

Expression of MUC1 in different tumours and its clinical significance (Review)

Contact Info

Product

Resources

About